Black Diamond Therapeutics
BDTX
94 hedge funds and large institutions have $95.8M invested in Black Diamond Therapeutics in 2025 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 27 closing their positions.
578% more call options, than puts
Call options by funds: $61K | Put options by funds: $9K
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
44% more capital invested
Capital invested by funds: $66.3M → $95.8M (+$29.5M)
37% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 27
12% more funds holding
Funds holding: 84 → 94 (+10)
4.01% less ownership
Funds ownership: 71.92% → 67.91% (-4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.42M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$638K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$463K |
| 4 |
Jane Street
New York
|
+$402K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$358K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.59M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.33M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.26M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$906K |
| 5 |
Morgan Stanley
New York
|
-$644K |
BDTX Hedge Fund Activity: Q2 2025 in Review
94 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2025, worth a combined $95.8M — up 44% from $66.3M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new BDTX positions and 27 closed out — a net gain of 10 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $1.42M. The largest seller was BlackRock, cutting an estimated $4.59M.
- 94 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2025, up from 84 in Q1 2025.
- Funds reported $95.8M of Black Diamond Therapeutics stock for Q2 2025, up 44% quarter-over-quarter.
- 37 funds opened new Black Diamond Therapeutics positions in Q2 2025 and 27 closed out, a net change of +10 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2025 was Marshall Wace, an estimated $1.42M added.
- The largest Black Diamond Therapeutics seller in Q2 2025 was BlackRock, an estimated $4.59M sold.
Based on aggregated 13F filings for Q2 2025.